Anchor
LSD-based pill clears late-stage anxiety trial
New CapabilitiesDefinium's single-dose lysergide tablet cut anxiety scores in its first Phase 3 study, with a second readout due in weeks
3 days ago: Voyage anxiety trial succeedsNew here? Follow stories to track developments over time. Create a free account to get updates when stories you care about change.
Overview
A single dose of LSD, taken as a tablet that dissolves under the tongue, cut anxiety scores for people with generalized anxiety disorder and held that benefit for 12 weeks. On August 12, 2026, Definium Therapeutics said its drug, DT120, beat placebo in its first large late-stage trial. The effect showed up by day two.
No approved anxiety drug works like this. Standard treatments are pills taken daily for weeks. DT120 is one supervised dose in a clinic. If a second trial due in September confirms the result, Definium could file for what would be the first approval of an LSD-based medicine.
Why it matters
Roughly 6% of U.S. adults have generalized anxiety disorder, and many get little help from daily pills. A single dose that works in days would change that.
Questions about this story
No questions yet — be the first to ask.
Key Indicators
5.4 points
Anxiety score gap vs. placebo
Placebo-adjusted drop on the Hamilton Anxiety Rating Scale at week 12 (p<0.0001).
43% vs 16%
Response rate
Share of patients with at least a 50% anxiety reduction, DT120 vs. placebo.
214
Trial participants
Adults aged 18 to 74 randomized across 35 U.S. sites in the Voyage study.
0.81
Effect size (Cohen's d)
A large effect by clinical-trial standards; Jefferies called it among the strongest seen in anxiety.
Related Media
Robert Barrow Chief Executive Officer at Definium Therapeutics
1.0K views
13:34
LSD for anxiety? Study finds one dose helps for months
FOX 32 Chicago
516 views
2:58
North Charleston researchers launch LSD clinical trial to treat ...
ABC News 4
3.2K views
7:32
DT120: A New LSD Drug to Treat Anxiety
Sibin
Images from Openverse under Creative Commons licenses. Videos from YouTube.
Voices
Curated perspectives — historical figures and your fellow readers.
Play
Exploring all sides of a story is often best achieved with Play.
Most of these play right now — no account needed. Sign up to save scores, keep a streak, and unlock Debate and Predict.
Log in
Sign Up
Higher or Lower
A number from this story, against one from elsewhere in the news — guess which is bigger, then keep the chain going. 5 rounds, 3 strikes; a miss costs a strike and resets your streak.
Example
Anchor
EU tariff revenue
$52B
Big for this kind of number
Mystery
Pentagon AI contract
?
Round 1
Streak: 0
Mystery
?
Keyboard: ↓/L lower · ↑/H higher
0 pts
Best streak: 0 · Rounds: 0
0 points — sign up to put that on the leaderboard.
Now try on this story
Timeline
LSD-based pill clears late-stage anxiety trial
Order five events from this story, oldest at top. Each in the right slot scores 1 — neighbours within one slot count too. Your previous result — green ✓ for exact slots, yellow ~ for off by one. Cards now in true chronological order.
Loading puzzle…
Tap 💡 Free hint to lock the oldest into slot 1 — that leaves just four to order. Type pills are clues.
0/5
Exact slot
0/5
Within 1
Sign up to save your score and track a streak across stories.
Now try on this story
Connections
Sixteen names from the news. Find the four hidden groups of four. Four mistakes max.
Loading today's puzzle…
0/4 groups
Mistakes
Sign up to keep a daily streak — a new puzzle lands every day.
Now try on this story
Exit debate?
Your progress in this debate will be lost.
How it works
- 1 Two AI personas square off on this story.
- 2 You predict who'll win each round — correct picks earn XP.
- 3 One crossfire question is yours to fire. Pick it carefully.
Couldn't generate a topic
Select Your Champions
Choose one persona for each side of the debate
DEBATE TOPIC
Choose personas with different perspectives for a more dynamic debate.
SIDE A (PRO)
Select debater for this side:
No debate personas available right now.
SIDE B (CON)
Select debater for this side:
No debate personas available right now.
VS
Get ready to make your prediction...
Round of
Claim
Evidence
Stakes
Crossfire Answer
Closing Statement
Claim
Evidence
Stakes
Crossfire Answer
Closing Statement
Your Crossfire Question
Generating arguments...
Who's Got This Round?
Make your prediction before the referee scores
The referee scores both sides on
Correct predictions earn +20 XP
· Press 1 or 2 to pick
Evidence
40%
Logic
30%
Detail
20%
Style
10%
Round Results
Your Pick
Not this time
(%)
Overall Score
/10
Your Pick
Not this time
(%)
Overall Score
/10
Set the Crossfire
Pick the question both personas must answer in the final round
Crafting crossfire questions...
Choosing a question earns +10 XP crossfire bonus
🏆
Total XP Earned
Cred Change
Predictions
Debate Oracle! You called every round!
Sharp Instincts! You know your debaters!
The Coin Flip Strategist! Perfectly balanced!
The Contrarian! Bold predictions!
Inverse Genius! Try betting the opposite next time!
XP Breakdown
Base completion
+20 XP
Rounds played ( rounds x 5 XP)
+ XP
Correct predictions ( correct x 20 XP)
+ XP
Crossfire bonus
+10 XP
Accuracy
%
Prediction History
Round
You picked:
✓
✗
Now try on this story
Keep debating to level up your credibility and unlock achievements
People Involved
Organizations Involved
Definium Therapeutics
Biotechnology company
Developer of DT120, the LSD-based tablet
A New York-based drug developer, formerly MindMed, betting its future on an LSD tablet for anxiety and depression.
U.S. Food and Drug Administration
Federal agency
Regulator deciding whether LSD becomes an approved medicine
The agency that reviews and approves drugs for the U.S. market.
Timeline
December 2023 August 2026
7 events
Latest: 3 days ago
Tap a bar to jump to that date
-
Voyage anxiety trial succeeds
Latest Clinical TrialDT120 beat placebo on the Hamilton Anxiety scale by 5.4 points at week 12, with effects from day two. It met every main and secondary goal.
-
FDA finalizes psychedelic trial rules
RegulatoryNew guidance spelled out how companies should design psychedelic studies, including how to handle patients guessing which treatment they got.
-
DT120 wins Phase 3 trial in depression
Clinical TrialThe Emerge study showed a single dose cut depression scores sharply within a week and held for weeks. It was the first Phase 3 win for the drug.
-
MindMed becomes Definium Therapeutics
CorporateThe company rebranded and began trading as DFTX. MM120 became DT120. The move signaled a pivot to late-stage psychiatry.
-
FDA rejects MDMA therapy for PTSD
RegulatoryThe agency turned down Lykos Therapeutics's MDMA-assisted therapy and asked for another trial. Unblinding worries loomed over the whole field.
-
FDA grants Breakthrough Therapy designation
RegulatoryThe FDA flagged the LSD program as promising enough for anxiety to warrant a faster review. Durability data showed the benefit held for 12 weeks.
-
MindMed's mid-stage anxiety trial hits its mark
Clinical TrialA single dose of MM120 cut anxiety scores far more than placebo at week four, with no required therapy. The result put an LSD drug on a serious path.
Historical Context
3 moments from history that rhyme with this story — and how they unfolded.
March 2019
Esketamine (Spravato) approval (2019)
The FDA approved Johnson & Johnson's esketamine, a chemical cousin of the party drug ketamine, as a nasal spray for treatment-resistant depression. Patients take it in a certified clinic and stay under watch for two hours because of dissociation and sedation.
Then
It became the first genuinely new mechanism approved for depression in decades, sold under strict in-clinic monitoring rules.
Now
It proved a mind-altering drug could win approval if given under supervision, creating the clinic-based model Definium now follows.
Why this matters now
DT120 uses the same playbook: a powerful psychoactive drug, one supervised dose, monitoring for hours. Esketamine showed regulators can say yes to this format.
August 2024
Lykos MDMA rejection (2024)
The FDA rejected Lykos Therapeutics's MDMA-assisted therapy for post-traumatic stress disorder and asked for another trial. An advisory panel had voted that the trials failed to prove the benefits outweighed the risks. Functional unblinding, patients knowing they got the drug, was a central worry.
Then
The first psychedelic therapy bid collapsed, and three related studies were retracted over conduct problems.
Now
It set a higher bar for the field and made unblinding the question every developer now has to answer.
Why this matters now
It is the cautionary tale Definium is designing around. The extra low-dose arm in Panorama exists to answer the exact objection that sank Lykos.
June 2025
Compass psilocybin Phase 3 (2025)
Compass Pathways reported that its synthetic psilocybin met the main goal of a Phase 3 depression trial. Investors were unconvinced by the size and durability of the effect, and the stock fell by nearly half.
Then
A technical trial success still triggered a sharp sell-off as the market questioned real-world impact.
Now
It showed that meeting an endpoint is not enough; the strength and staying power of the effect decide how a readout lands.
Why this matters now
Definium's larger effect size and day-two onset are exactly the features that Compass was seen to lack, which is why the Voyage numbers drew a different reaction.